EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Effectiveness of Recombinant Human Growth Hormone Therapy in Small‐for‐Gestational‐Age Children With Short Stature: A Stratified Analysis Based on Genetic Variant Status

Sanghee Park, Yena Lee, Hwal Rim Jeong, Eun Young Kim, Eu-Seon Noh, Hye Young Jin, Eun Byul Kwon, Hye Jin Lee, Young-Jun Seo, Young Suk Shim, Su Jin Kim, Ji-Eun Lee und 4 weitere

Clinical Endocrinology · 02.08.2026

DOI: 10.1111/cen.70186 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Endocrinology, online erschienen am 02.08.2026. Verfasst von Sanghee Park und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Hallym University Kangnam Sacred Heart Hospital, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Human Growth Hormone, Infant, Small for Gestational Age, Growth Disorders, Dwarfism. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to evaluate the impact of pathogenic genetic variants on growth outcomes following 3 years of recombinant human growth hormone (rhGH) therapy in children born small for gestational age with persistent short stature (SGA‐SS).

Design

A retrospective cohort study. Patients One hundred and seventy‐nine SGA‐SS children who underwent clinical and genetic evaluation were classified into variant‐positive ( n = 30) and variant‐negative groups ( n = 149).

Measurements

Clinical characteristics and growth outcomes were assessed over 3 years of rhGH therapy.

Results

At baseline, the variant‐positive group had significantly lower height standard deviation score (SDS) (−2.83 vs. −2.28, p < 0.001) and higher rates of intellectual disability (36.7% vs. 7.4%, p < 0.001) and congenital anomalies (30.0% vs. 6.7%, p < 0.001). rhGH therapy promoted longitudinal growth in both groups (evaluated n = 142); after 3 years, the estimated marginal mean (EMM) of height SDS reached −1.30 ± 0.10 in the variant‐positive group and −0.93 ± 0.04 in the variant‐negative group. However, linear mixed model analysis revealed a progressive attenuation of incremental height SDS gain in the variant‐positive group as the treatment progressed, with significant interaction estimates observed at Year 1 (Estimate −0.18), Year 2 (Estimate −0.31) and Year 3 (Estimate −0.36; all p < 0.05).

Conclusion

As one of the first longitudinal analyses utilizing repeated‐measures modelling in a genetically characterized patient population, this study demonstrates that while rhGH therapy effectively promoted linear growth in SGA‐SS children, patients with a molecular diagnosis presented with lower baseline stature and an attenuated incremental growth response over time, highlighting the importance of genetic evaluation for personalized treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Human Growth HormoneInfant, Small for Gestational AgeGrowth DisordersDwarfismHumansFemaleRetrospective StudiesMaleChildBody HeightRecombinant ProteinsChild, PreschoolInfant, NewbornGenetic VariationTreatment Outcome

Stichwörter der Autor:innen

genetic variantsgrowth hormoneshort staturesmall for gestational age

Substanzen

Human Growth HormoneRecombinant Proteins

Autor:innen und Institutionen

  • Department of Pediatrics, Hallym University Kangnam Sacred Heart Hospital, Seoul, Republic of Korea.
  • Department of Pediatrics, Hallym University Sacred Heart Hospital, Anyang, Republic of Korea.
  • Department of Pediatrics, College of Medicine, Soonchunhyang University, Cheonan, Republic of Korea.
  • Department of Pediatrics, Chosun University Hospital, Gwangju, Republic of Korea.
  • Department of Pediatrics, Kangdong Sacred Heart Hospital, Seoul, Republic of Korea.
  • The Key Growth Clinic, Seongnam, Gyeonggi-do, Republic of Korea.

ORCID-Profile: Min Jae Kang, Il Tae Hwang

Zitieren

APA

Park, S., Lee, Y., Jeong, H. R., Kim, E. Y., Noh, E. S., Jin, H. Y., Kwon, E. B., Lee, H. J., Seo, Y. J., Shim, Y. S., Kim, S. J., Lee, J. E., Kim, N. Y., Hong, S., Kang, M. J., & Hwang, I. T. (2026). Effectiveness of Recombinant Human Growth Hormone Therapy in Small‐for‐Gestational‐Age Children With Short Stature: A Stratified Analysis Based on Genetic Variant Status. Clinical Endocrinology. https://doi.org/10.1111/cen.70186

Vancouver

Park S, Lee Y, Jeong HR, Kim EY, Noh ES, Jin HY, et al. Effectiveness of Recombinant Human Growth Hormone Therapy in Small‐for‐Gestational‐Age Children With Short Stature: A Stratified Analysis Based on Genetic Variant Status. Clinical Endocrinology. 2026. doi:10.1111/cen.70186

BibTeX
@article{Park2026,
  author = {Park, Sanghee and Lee, Yena and Jeong, Hwal Rim and Kim, Eun Young and Noh, Eu-Seon and Jin, Hye Young and Kwon, Eun Byul and Lee, Hye Jin and Seo, Young-Jun and Shim, Young Suk and Kim, Su Jin and Lee, Ji-Eun and Kim, Nan Young and Hong, Sangkyoon and Kang, Min Jae and Hwang, Il Tae},
  title = {Effectiveness of Recombinant Human Growth Hormone Therapy in Small‐for‐Gestational‐Age Children With Short Stature: A Stratified Analysis Based on Genetic Variant Status},
  journal = {Clinical Endocrinology},
  year = {2026},
  doi = {10.1111/cen.70186}
}
Kostenlos starten →